In db/db mice, Imidapril administered in drinking water significantly increased urine AcSDKP concentration compared with vehicle alone. In streptozotocin-treated CD-1 mice, Imidapril administered in drinking water partially decreased interstitial fibrosis compared with untreated diabetic mice. In pure strain male NMRI mice bearing MAC16 tumours, oral Imidapril administered by gavage attenuated the development of weight loss compared with water controls, with a dose-related effect. In another study in db/db mice, Imidapril administered in drinking water significantly suppressed glomerular mesangial area expansion compared with no treatment. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Imidapril increases urinary AcSDKP in db/db mice
Animal study · db/db mice [1]
In db/db mice, Imidapril administered in drinking water significantly increased urine AcSDKP concentration compared with vehicle alone.
Conditions shared by the study groups
- Route
- in the drinking water
- Treatment course
- At 20 weeks of age; euthanized at 24 weeks of age
- Imidapril 2.5 mg/kg BW/day
- Model: db/db mice
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Imidapril
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Materials and Methods > 2.2. Animal Experiments (S11, S12, S13); 3. Results > 3.1. Elevation of Both Plasma and Urine AcSDKP Levels after the Oral Administration of AcSDKP (S54)
urine AcSDKP concentration: urine AcSDKP concentration; comparator: vehicle alone — 2. Materials and Methods > 2.2. Animal Experiments (S11); 3. Results > 3.1. Elevation of Both Plasma and Urine AcSDKP Levels after the Oral Administration of AcSDKP (S54)
Imidapril 2.5 mg/kg BW/day · 2. Materials and Methods > 2.2. Animal Experiments (S11, S12, S13); 3. Results > 3.1. Elevation of Both Plasma and Urine AcSDKP Levels after the Oral Administration of AcSDKP (S54)
Imidapril partially decreases interstitial fibrosis in diabetic mice
Animal study · streptozotocin- (STZ-) treated CD-1 mice [2]
In streptozotocin-treated CD-1 mice, Imidapril administered in drinking water partially decreased interstitial fibrosis compared with untreated diabetic mice.
Conditions shared by the study groups
- Route
- in drinking water
- Treatment course
- Sixteen weeks after the induction of diabetes; euthanized 24 weeks after the induction of diabetes
- Imidapril 2.5 mg/kg BW/day
- Model: streptozotocin- (STZ-) treated CD-1 mice
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Imidapril
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Materials and Methods > 2.2. Animal Experiments (S10, S12, S14, S15, S16); 3. Results > 3.1. Antifibrotic Effect of AcSDKP on the Top of ACE-I (S58); Figure 2 legend (S99)
relative area of fibrosis: relative area of fibrosis; comparator: untreated diabetic mice — 2. Materials and Methods > 2.2. Animal Experiments (S14); 3. Results > 3.1. Antifibrotic Effect of AcSDKP on the Top of ACE-I (S58); Figure 2 legend (S99)
Imidapril 2.5 mg/kg BW/day · 2. Materials and Methods > 2.2. Animal Experiments (S14, S15, S16); 3. Results > 3.1. Antifibrotic Effect of AcSDKP on the Top of ACE-I (S58)
Imidapril attenuates weight loss in tumour-bearing mice
Animal study · Pure strain male NMRI mice; MAC16 tumour; n=10 initially [3]
At a dose level of 30 mg kg−1, imidapril attenuated the development of weight loss. The effect was dose related and was not seen with lower dose levels (3 mg kg−1). The shapes of the curves were significantly different (P<0.001).
Conditions shared by the study groups
- Route
- orally three times daily by gavage
- Treatment course
- three times daily
- Vehicle
- water
- Imidapril 10 mg kg−1; orally three times daily by gavage
- Model: Pure strain male NMRI mice; MAC16 tumour; n=10 initially
Methods and source locations
Compound reported in the paper: Imidapril
Evidence for Imidapril as the hydrochloride form reported in the paper, not the free base/neutral form supplied as A11867; no salt equivalence, dose conversion or lot validation.
MATERIALS AND METHODS > Animals (S10, S12); RESULTS (S65, S66); Figure 8 legend (S93, S94, S95, S96)
body weight: body weight; comparator: water controls — RESULTS (S65, S66); Figure 8 legend (S93, S96)
Imidapril 10 mg kg−1; orally three times daily by gavage · MATERIALS AND METHODS > Animals (S12); RESULTS (S65, S66); Figure 8 legend (S94, S96)
Imidapril suppresses glomerular mesangial expansion in db/db mice
Animal study · db/db mice [1]
In db/db mice, Imidapril administered in drinking water significantly suppressed glomerular mesangial area expansion compared with no treatment.
Conditions shared by the study groups
- Route
- in the drinking water
- Treatment course
- At 20 weeks of age; At 24 weeks of age, all mice were euthanized
- Imidapril 2.5 mg/kg BW/day
- Model: db/db mice
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Imidapril
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Materials and Methods > 2.2. Animal Experiments (S11, S12); 3. Results > 3.2. A Higher Level of AcSDKP was Associated with Antifibrotic Effects in the Kidney (S75); Figure 4 legend (S126, S128, S130)
Morphometric analyses for mesangial expansion: Morphometric analyses for mesangial expansion; comparator: no treatment — 2. Materials and Methods > 2.2. Animal Experiments (S11); 3. Results > 3.2. A Higher Level of AcSDKP was Associated with Antifibrotic Effects in the Kidney (S75); Figure 4 legend (S130)
Imidapril 2.5 mg/kg BW/day · 2. Materials and Methods > 2.2. Animal Experiments (S11, S12); 3. Results > 3.2. A Higher Level of AcSDKP was Associated with Antifibrotic Effects in the Kidney (S75); Figure 4 legend (S126, S128)